enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Growth in Short Interest

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a large increase in short interest in the month of October. As of October 15th, there was short interest totalling 813,000 shares, an increase of 63.1% from the September 30th total of 498,500 shares. Currently, 4.6% of the company's stock are short sold. Based on an average daily volume of 195,500 shares, the short-interest ratio is currently 4.2 days.

enGene Trading Up 1.9 %

Shares of ENGN stock traded up $0.17 during trading hours on Friday, hitting $9.07. 135,876 shares of the company were exchanged, compared to its average volume of 382,398. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene has a one year low of $4.42 and a one year high of $43.00. The business's 50-day simple moving average is $7.03 and its two-hundred day simple moving average is $9.43.

enGene (NASDAQ:ENGN - Get Free Report) last issued its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.37) by $0.05. On average, equities research analysts forecast that enGene will post -1.56 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of the firm's stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $5.97 per share, with a total value of $248,584.83. Following the transaction, the insider now directly owns 2,059,459 shares in the company, valued at approximately $12,294,970.23. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, major shareholder Growth Opportunities F. Forbion acquired 341,332 shares of the firm's stock in a transaction on Monday, September 30th. The stock was bought at an average cost of $6.34 per share, with a total value of $2,164,044.88. Following the transaction, the insider now directly owns 2,400,791 shares in the company, valued at approximately $15,221,014.94. This represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of the firm's stock in a transaction on Friday, September 27th. The stock was purchased at an average cost of $5.97 per share, with a total value of $248,584.83. Following the completion of the transaction, the insider now owns 2,059,459 shares in the company, valued at $12,294,970.23. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 420,965 shares of company stock valued at $2,651,103. Company insiders own 13.70% of the company's stock.

Hedge Funds Weigh In On enGene

Large investors have recently bought and sold shares of the business. Altitude Crest Partners Inc. acquired a new position in shares of enGene during the first quarter valued at approximately $2,039,000. Logos Global Management LP increased its stake in shares of enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company's stock valued at $11,316,000 after acquiring an additional 400,000 shares during the period. SR One Capital Management LP acquired a new position in enGene in the second quarter worth approximately $4,715,000. Finally, Janus Henderson Group PLC acquired a new position in enGene in the first quarter worth approximately $17,095,000. Institutional investors own 64.16% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Oppenheimer reissued an "outperform" rating and issued a $30.00 price objective on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reaffirmed an "overweight" rating and set a $40.00 price target on shares of enGene in a research report on Wednesday, September 11th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, enGene has an average rating of "Buy" and an average target price of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.